On January 6, 2023, the Food and Drug American Agency (FDA) approved LEQEMBI for the treatment of Alzheimer’s disease. It belongs to the monoclonal antibody family and binds ß-amyloid fibres by disaggregating them.
Recent studies suggest a new revolutionary approach in detecting primitive stages of Alzheimer's disease through the identification of specific biomarkers many years before clinical signs are evident. Let's take a closer look.
Sodium oligomannate, a natural product derived from brown seaweed, is the first new compound approved for the treatment of Alzheimer's disease since 2003. Can a simple sugar be a new cure for patients? This article will give you some hints.